Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Diabetes AND Sitagliptin AND Metformin

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44337   clinical trials with a EudraCT protocol, of which   7367   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    110 result(s) found for: Diabetes AND Sitagliptin AND Metformin. Displaying page 1 of 6.
    1  2  3  4  5  6  Next»
    EudraCT Number: 2020-003731-22 Sponsor Protocol Number: MK-0431A-296 Start Date*: 2020-09-03
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Study to Assess the Pharmacokinetics and Ability for Pediatric Patients with Type 2 Diabetes to Swallow MK-0431A XR Tablets
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    21.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2007-006074-28 Sponsor Protocol Number: 0893-015 Start Date*: 2008-02-21
    Sponsor Name:Merck Sharp & Dohme (Sweden) AB
    Full Title: A Phase IIa, Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy and Safety of MK-0893 in Combination With Sitagliptin or in Combination With Me...
    Medical condition: Type II Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    9.1 10045242 Type II diabetes mellitus LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed) ES (Completed) DK (Completed) DE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2008-004916-12 Sponsor Protocol Number: D1690C00007 Start Date*: 2008-11-11
    Sponsor Name:AstraZeneca AB
    Full Title: A 24-Week, International, Multi-centre, Randomised, Parallel-group, Double-blind, Active-controlled, Phase III study to Evaluate the Efficacy and Safety of Dapagliflozin in Combination with Metform...
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012613 Diabetes mellitus non-insulin-dependent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) DE (Prematurely Ended) AT (Prematurely Ended) CZ (Prematurely Ended) GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-003583-20 Sponsor Protocol Number: 0431A-170-03 Start Date*: 2014-12-30
    Sponsor Name:Merck Sharp & Dohme Corp. a subsidiary of Merck & Co., Inc
    Full Title: A Phase III, Multicenter, Double-Blind, Randomized, Placebo -Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-0431A (A Fixed-Dose Combination Tablet of Sitagliptin and Metformin...
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-004137-42 Sponsor Protocol Number: 0431-066 Start Date*: 2007-10-28
    Sponsor Name:Merck Sharp & Dohme GmbH
    Full Title: A Phase III Randomized, Active-Comparator (Pioglitazone) Controlled Clinical Trial to Study the Efficacy and Safety of MK-0431A (A Fixed-Dose Combination Tablet of Sitagliptin and Metformin) in Pat...
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    9.1 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) IE (Completed) HU (Completed) SE (Completed) SI (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-004930-33 Sponsor Protocol Number: BIASP-3963 Start Date*: 2012-04-02
    Sponsor Name:Novo Nordisk A/S
    Full Title: A 24 week randomised, open label, 3 parallel-group comparison of once and twice daily biphasic insulin aspart (BIAsp) 30 plus sitagliptin and twice daily BIAsp 30, all in combination with metfor...
    Medical condition: Diabetes Mellitus, Type 2
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2007-000019-27 Sponsor Protocol Number: 0431-049 Start Date*: 2007-03-14
    Sponsor Name:Merck & Co., Inc
    Full Title: A Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of Sitagliptin Compared With Metformin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control
    Medical condition: type II diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    9.1 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) FI (Completed) IE (Completed) HU (Completed) DK (Completed) ES (Completed) GB (Completed) AT (Completed) GR (Completed) DE (Completed) EE (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2015-004224-59 Sponsor Protocol Number: MK-0431-848 Start Date*: 2016-07-27
    Sponsor Name:Merck Sharp & Dohme Corp.
    Full Title: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of the Addition of Sitagliptin During Metformin Up-titration Compared with Met...
    Medical condition: Type 2 Diabetes mellitus
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2008-001050-40 Sponsor Protocol Number: NN304-3511 Start Date*: 2008-10-29
    Sponsor Name:Novo Nordisk A/S
    Full Title: A 26 week randomised, open labelled, parallel group, multi-national, treat-to-target trial comparing efficacy and safety of insulin detemir once daily in combination with sitagliptin and metformin ...
    Medical condition: type 2 diabetes
    Disease: Version SOC Term Classification Code Term Level
    9.1 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) HU (Completed) SK (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2014-002685-70 Sponsor Protocol Number: 300A Start Date*: 2015-08-03
    Sponsor Name:Lund University
    Full Title: The Effect of Sitagliptin on Glucagon Dynamics and Incretin Hormones During Mild Hypoglycemia in Elderly Patients with Metformin-Treated Type 2 Diabetes
    Medical condition: Type 2 Diabetes Mellitus
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2011-003600-20 Sponsor Protocol Number: MK-0431E-211 Start Date*: 2012-08-02
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Co-Administration of Sitagliptin and Atorvastatin in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Co...
    Medical condition: Type 2 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    15.0 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) HU (Prematurely Ended) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-004622-96 Sponsor Protocol Number: 0431-260 Start Date*: 2011-12-23
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (hereafter referred to as
    Full Title: A Phase III, Multicenter, Randomized, Double-Blind, Placebo- Controlled Clinical Trial to Study the Safety and Insulin-Sparing Efficacy of the Addition of Sitagliptin in Patients With Type 2 Diabet...
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    14.0 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) IE (Completed) LT (Completed) DK (Completed) HU (Completed) BE (Completed) GB (Completed) IT (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2011-002528-42 Sponsor Protocol Number: 0431-083 Start Date*: 2011-12-30
    Sponsor Name:Merck Sharp & Dohme Corp. A subsidiary of Merck & Co. Inc
    Full Title: A Phase III, Multicenter, Double-Blind, Randomized, Placebo- and Metformin-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Sitagliptin in Pediatric Patients with Type 2 Diabetes Me...
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: LV (Completed) LT (Completed) DE (Completed) ES (Prematurely Ended) IT (Completed) BG (Completed) AT (Completed) DK (Completed) SE (Completed) HU (Completed) PL (Completed) SK (Completed) Outside EU/EEA GR (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2010-018318-62 Sponsor Protocol Number: 0431-229 Start Date*: 2010-06-01
    Sponsor Name:Merck & Co., Inc.
    Full Title: A Phase III, Randomized, Clinical Trial to Evaluate the Safety and Efficacy of the Addition of Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on a Sulfon...
    Medical condition: Diabetes Mellitus type 2
    Disease: Version SOC Term Classification Code Term Level
    12.1 10067585 Type 2 diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2011-002529-23 Sponsor Protocol Number: 0431A-170 Start Date*: 2011-12-30
    Sponsor Name:Merck Sharp & Dohme Corp., a Subsidiary of Merck & Co.
    Full Title: MK-0431A Protocol 170-04: “A Phase III, Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy MK-0431A (A Fixed-Dose Combination Tablet of Si...
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: LV (Completed) LT (Prematurely Ended) GB (Completed) IT (Completed) DE (Completed) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-000518-21 Sponsor Protocol Number: CLMF237ADE02 Start Date*: 2011-06-20
    Sponsor Name:Novartis Pharma GmbH
    Full Title: Cross-over study to assess the difference in fasting plasma glucose (FPG) between vildagliptin (Galvus®/Eucreas®) and sitagliptin (Januvia®/Janumet®) after two weeks (FPG-VISIT)
    Medical condition: Diabetes mellitus type 2
    Disease: Version SOC Term Classification Code Term Level
    13.1 10027433 - Metabolism and nutrition disorders 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-004035-23 Sponsor Protocol Number: 0431A-0289 Start Date*: 2013-03-20
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase III Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-0431A XR (a Fixed-Dose Combination Tablet of Sitagliptin and Extended-...
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: CZ (Completed) IT (Completed) HU (Completed) DK (Completed) BG (Prematurely Ended) Outside EU/EEA GR (Completed)
    Trial results: View results
    EudraCT Number: 2006-005051-15 Sponsor Protocol Number: 0431-051 Start Date*: 2007-01-15
    Sponsor Name:Merck & Co., Inc.
    Full Title: A Phase III, Multicenter, Randomized, Double-Blind Clinical Trial to Study the Safety and Efficacy of the Addition of Sitagliptin (MK-0431) to Patients with Type 2 Diabetes Mellitus Who Have Inade...
    Medical condition: type II Diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    8.1 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) IE (Completed) DK (Completed) FI (Completed) BE (Completed) FR (Completed) PT (Completed) AT (Prematurely Ended) IT (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2012-004931-22 Sponsor Protocol Number: NN2211-4059 Start Date*: 2013-10-17
    Sponsor Name:Novo Nordisk A/S
    Full Title: Efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes not achieving adequate glycaemic control on sitagliptin and metformin
    Medical condition: Diabetes Mellitus, Type 2
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2008-007334-22 Sponsor Protocol Number: EFC10780 Start Date*: 2009-11-02
    Sponsor Name:Sanofi-Aventis Recherche & Développement
    Full Title: A randomized, double-blind, double-dummy, 2-arm parallel-group, multicenter 24-week study comparing the efficacy and safety of AVE0010 to sitagliptin as add-on to metformin in obese type 2 diabetic...
    Medical condition: Type II Diabetes
    Disease: Version SOC Term Classification Code Term Level
    11.1 10045242 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 22 07:40:50 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA